A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma


Full Title

A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma


The purpose of this study is to find the highest dose of the investigational drug ADCT-301 that can be given safely in patients with Hodgkin and non-Hodgkin lymphoma that has continued to grow or came back despite prior treatment.

ADCT-301 is an “antibody-drug conjugate.” It contains two parts: an antibody that binds to a protein on lymphoma cells called CD25, and an anticancer drug. ADCT-301 finds cancer cells, binds to them, and then releases the drug to kill the cancer cell. It is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Hodgkin or non-Hodgkin lymphoma that has returned or continued to grow despite prior treatment.
  • At least 3 weeks must pass between the completion of previous therapies and entry into the study, and patients must recover from any serious side effects.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.